Abacus Planning Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$318K Buy
5,517
+9
+0.2% +$517 0.04% 199
2026
Q1
$334K Sell
5,508
-224
-4% -$13.1K 0.05% 186
2025
Q4
$309K Buy
5,732
+98
+2% +$4.71K 0.04% 191
2025
Q3
$254K Sell
5,634
-343
-6% -$16K 0.04% 211
2025
Q2
$277K Sell
5,977
-42
-0.7% -$2.06K 0.04% 193
2025
Q1
$367K Buy
6,019
+75
+1% +$4.37K 0.06% 149
2024
Q4
$336K Buy
5,944
+20
+0.3% +$1.12K 0.06% 153
2024
Q3
$307K Sell
5,924
-222
-4% -$10.4K 0.05% 163
2024
Q2
$255K Sell
6,146
-4,273
-41% -$191K 0.05% 176
2024
Q1
$565K Buy
10,419
+1,901
+22% +$96.8K 0.11% 100
2023
Q4
$437K Sell
8,518
-2,373
-22% -$125K 0.09% 112
2023
Q3
$632K Sell
10,891
-731
-6% -$44.8K 0.15% 88
2023
Q2
$743K Buy
11,622
+794
+7% +$53.2K 0.18% 81
2023
Q1
$750K Sell
10,828
-120
-1% -$8.46K 0.19% 81
2022
Q4
$788K Buy
10,948
+969
+10% +$73.1K 0.22% 72
2022
Q3
$709K Buy
9,979
+160
+2% +$11.6K 0.21% 74
2022
Q2
$756K Buy
9,819
+173
+2% +$13.2K 0.22% 79
2022
Q1
$704K Sell
9,646
-81
-0.8% -$5.44K 0.19% 91
2021
Q4
$606K Sell
9,727
-163
-2% -$9.56K 0.16% 97
2021
Q3
$585K Buy
9,890
+58
+0.6% +$3.82K 0.19% 90
2021
Q2
$657K Sell
9,832
-399
-4% -$26K 0.2% 83
2021
Q1
$646K Sell
10,231
-100
-1% -$6.22K 0.21% 86
2020
Q4
$641K Hold
10,331
0.2% 83
2020
Q3
$623K Hold
10,331
0.23% 76
2020
Q2
$607K Buy
10,331
+150
+1% +$8.97K 0.25% 74
2020
Q1
$567K Buy
10,181
+1,247
+14% +$76.2K 0.28% 68
2019
Q4
$573K Buy
8,934
+69
+0.8% +$3.95K 0.26% 76
2019
Q3
$450K Buy
8,865
+1,111
+14% +$52.2K 0.22% 88
2019
Q2
$352K Buy
7,754
+49
+0.6% +$2.28K 0.21% 104
2019
Q1
$368K Hold
7,705
0.23% 93
2018
Q4
$401K Sell
7,705
-7,680
-50% -$413K 0.3% 81
2018
Q3
$955K Hold
15,385
0.64% 35
2018
Q2
$851K Hold
15,385
0.64% 36
2018
Q1
$973K Buy
15,385
+3,076
+25% +$198K 0.79% 28
2017
Q4
$754K Buy
+12,309
New +$770K 0.76% 30

Other funds holding BMY

Abacus Planning Group's BMY Position: Q2 2026 in Review

Abacus Planning Group increased its Bristol-Myers Squibb (BMY) stake by 0.16% in Q2 2026, buying an estimated $517 and bringing the position to 5,517 shares worth $318K. The position accounts for 0.04% of the portfolio, ranked #199.

Abacus Planning Group first reported a position in BMY in Q4 2017 and has held it in 35 quarters since. The position peaked at $973K in Q1 2018. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Abacus Planning Group held 5,517 shares of Bristol-Myers Squibb worth $318K as of Q2 2026.
  • Abacus Planning Group bought 9 Bristol-Myers Squibb shares in Q2 2026, an estimated $517.
  • Bristol-Myers Squibb made up 0.04% of Abacus Planning Group's portfolio in Q2 2026, its #199 holding.
  • Abacus Planning Group first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 35 quarters since.
  • Abacus Planning Group's Bristol-Myers Squibb position peaked at $973K in Q1 2018.
  • 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Abacus Planning Group's 13F filing for Q2 2026, filed 20 Jul 2026.